HanstenPDHornJR. Pitfalls in the evaluation of drug interaction literature. In: Hansten PD, Horn JR. Drug interactions and updates quarterly. Vancouver: Applied Therapeutics, 1993: 31–4.
2.
KishoreKRainaAMisraVJonasE. Acute verapamil toxicity in a patient with chronic toxicity: possible interaction with ceftriaxone and clindamycin. Ann Pharmacother1993; 27: 877–80.
3.
HanstenPDHornJR. Pharmacokinetic drug interaction mechanisms and clinical characteristics. In: HanstenPDHornJR. Drug interactions and updates quarterly. Vancouver: Applied Therapeutics, 1993: 1–24.
4.
DuverneCBoutenADeslandesAWestphalJ-FTrouvinJ-HFarinottiRModifications of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. Antimicrob Agents Chemother1992; 36: 2462–7.
5.
EchizenHBrechtTNiedergesassSVogelgesangBEichelbaumM. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J1985; 109: 210–7.
6.
StoeckelKMcNamaraPJBrandtRPlozza-NottebrockHZieglerWH. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther1981; 29: 650–7.
7.
McGowanFXReiterMJPritchettELCShandDG. Verapamil plasma binding: relationship to alpha1-acid glycoprotein and drug efficacy. Clin Pharmacol Ther1983; 33: 485–90.
8.
KeefeDLYeeY-GKatesRE. Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther1981; 29: 21–6.
9.
SchwartzJB. Aging alters verapamil elimination and dynamics: single dose and steady-state responses. J Pharmacol Exp Ther1990; 255: 364–73.
10.
EchizenHVogelgesangBEichelbaumM. Effects of d, l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther1985; 38: 71–6.
11.
DasguptaADennenDADeanRMcLawhonRW. Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin, and sulfamethoxazole. Clin Chem1991; 37: 98–100.
